Core Viewpoint - The U.S. Federal Circuit Court confirmed the validity of certain claims of U.S. Patent No. 10,702,385 owned by Cardiovalve Ltd., which relates to heart valve implants, amidst challenges from Edwards Lifesciences Corp. and Edwards Lifesciences LLC [1] Group 1 - Cardiovalve Ltd. filed a patent infringement lawsuit against Edwards on January 14, 2026, in the U.S. District Court for the District of Delaware, alleging that Edwards' core product, the PASCAL Precision transcatheter valve repair system, infringes on the U.S. Patent No. 10,702,385 [1] - The lawsuit is still in its preliminary stages, and further details, including potential claims for damages, will depend on the outcome of the litigation [1] - The company will make further announcements regarding any substantial developments in the lawsuit in accordance with the rules of the Hong Kong Stock Exchange [1]

Core Viewpoint - The announcement by Qiming Medical-B (02500) highlights a legal ruling regarding the validity of a patent owned by Cardiovalve Ltd., which may impact the competitive landscape in the heart valve implant market [1] Group 1: Patent Litigation - On June 9, 2025, the U.S. Court of Appeals confirmed the validity of several claims of U.S. Patent No. 10,702,385 (heart valve implant) owned by Cardiovalve Ltd. [1] - Edwards Lifesciences Corp. and Edwards Lifesciences LLC challenged this patent in a reexamination process in June 2021 [1] - Cardiovalve Ltd. and MTH IP, L.P. filed a patent infringement lawsuit against Edwards on January 14, 2026, claiming that Edwards' core product, the PASCAL Precision transcatheter valve repair system, infringes on the patent [1] Group 2: Legal Proceedings - The litigation is still in its preliminary stages, and further details, including potential claims for damages, will depend on the outcome of the lawsuit [1] - The company will provide further announcements regarding any substantial developments in the lawsuit in accordance with the rules of the Hong Kong Stock Exchange [1]

Core Viewpoint - The article highlights that Qiming Medical-B (02500) has initiated a patent infringement lawsuit against Edwards Lifesciences in the U.S., marking a significant step in the company's legal strategy to protect its intellectual property rights and enhance its competitive position in the global medical device market [1]. Group 1: Company Actions - Qiming Medical's subsidiary Cardiovalve has filed a lawsuit in the U.S. District Court of Delaware against Edwards, alleging that its PASCAL Precision transcatheter valve repair system infringes on Cardiovalve's U.S. Patent No. 10,702,385 [1]. - This legal action follows Qiming Medical's previous victory in July 2025, where it successfully upheld the validity of its US'385 patent against Edwards [1]. Group 2: Industry Implications - Analysts view this lawsuit as a proactive measure by Qiming Medical to defend its innovations, representing a milestone for Chinese medical device companies in leveraging a robust intellectual property system for global market competition [1].

Core Viewpoint - The article highlights that Qiming Medical's subsidiary Cardiovalve has filed a patent infringement lawsuit against Edwards Lifesciences in the U.S., marking a significant step in the company's legal strategy to protect its intellectual property rights and enhance its competitive position in the global medical device market [1]. Group 1: Company Actions - Qiming Medical's stock price increased by over 14% during trading, with a current price of HKD 3.65 and a trading volume of HKD 26.28 million [1]. - The lawsuit was filed in the Delaware District Court, accusing Edwards of infringing on Cardiovalve's U.S. Patent No. 10,702,385 related to its PASCAL Precision transcatheter valve repair system [1]. Group 2: Industry Implications - Analysts view this legal action as a proactive measure by Qiming Medical following its previous victory in July 2025 regarding the validity of the US'385 patent, emphasizing the importance of intellectual property in the competitive landscape of the medical device industry [1]. - This case is seen as a milestone for Chinese medical device companies in their globalization efforts, showcasing the role of a robust intellectual property system in market competition [1].

Core Viewpoint - Edwards Lifesciences continues to showcase its commitment to the structural heart disease field by participating in the China International Import Expo for the sixth consecutive year, highlighting its innovative products and treatment solutions [1] Group 1: Product Launch and Innovation - Edwards Lifesciences presented the PASCAL Precision transcatheter valve repair system, marking its debut at the expo following its launch in Hong Kong [1] - The PASCAL Precision system offers a minimally invasive and reliable intervention option for high-risk surgical patients with mitral and tricuspid regurgitation, with expectations for approval in mainland China next year [1] Group 2: Strategic Partnerships - Edwards has upgraded its strategic collaborations with key industry partners such as Sinopharm Group and Shanghai Pharmaceuticals, aiming to enhance the introduction of advanced technologies and clinical transformation [1] - Wayne Markowitz, Global Vice President for Japan and Asia Pacific, emphasized the company's patient-first philosophy and the importance of the expo as a platform for collaboration [1] Group 3: Market Expansion - The participation in the expo signifies Edwards' efforts to accelerate the extension of its innovative achievements in transcatheter valve repair to the Chinese market [1] - The company aims to leverage the expo as an open window for accelerating the introduction of cutting-edge technologies [1]

Core Insights - The healthcare industry is demonstrating remarkable resilience in response to changing times, with a projected global market growth of 9% in 2024 driven by innovations in specialized treatments, explosive growth in anti-obesity drugs, and widespread application of AI in healthcare [1] - The China International Import Expo (CIIE) serves as a vital platform for global pharmaceutical companies to integrate deeply with the Chinese market and advance the Healthy China strategy [1][2] Industry Trends - The Chinese government has introduced policies to develop the healthcare industry and encourage innovative drug research, positioning China as a potential global center for biopharmaceutical innovation [2] - Major chronic diseases, such as cardiovascular and chronic kidney diseases, pose significant public health challenges in China, with over 400 million patients affected [2] Innovations and Product Launches - At the CIIE, various pharmaceutical companies showcased innovations across multiple fields, including cardiovascular, metabolic, respiratory, and oncology, highlighting their commitment to addressing major health challenges [1] - Novartis introduced the "Heart and Kidney Guardian Evidence-Based Science Popularization" project, emphasizing the dual role of pharmaceutical companies in drug development and public health education [3] - Sanofi launched two innovative cardiovascular drugs, Aficamten and Plerixafor, at the CIIE, addressing unmet patient needs in the treatment of cardiovascular diseases [3] - Roche presented advancements in blood cancer treatments, including new indications for existing therapies and innovative products for hemophilia [5] Strategic Collaborations - Siemens Healthineers and Novartis signed a strategic cooperation agreement to advance the integration of radioligand therapy and molecular imaging systems for precision treatment of diseases like prostate cancer [19] - Novo Nordisk and the Shanghai Clinical Innovation and Translation Research Institute (ACITS) established a strategic partnership to enhance clinical research and innovation in China [16][17] Public Health Initiatives - The CIIE featured discussions on the application of digital technology and AI in public health, aligning with China's "Healthy China 2030" strategy [21][23] - Pfizer emphasized the role of big data and AI in transforming public health systems and achieving health goals in China [23] Emerging Companies and Products - Viseon Pharmaceuticals showcased two innovative drugs at the CIIE, highlighting its commitment to global innovation and rapid market entry in China [24]